Results 201 to 210 of about 1,177,924 (224)
KMT2A degradation is observed in decitabine‐responsive acute lymphoblastic leukemia cells
Molecular Oncology, Volume 19, Issue 5, Page 1404-1421, May 2025.We demonstrate that decitabine (DEC) not only degrades the DNA methyltransferase DNMT1 but also the leukemic driver lysine methyltransferase KMT2A likely due to structural similarity of the DNA‐binding CXXC domains. DEC influences KMT2A downstream processes and synergizes with menin inhibitor revumenib (REV) to decrease leukemic cell proliferation, and
Luisa Brock +10 more
wiley +1 more source
Molecular Oncology, Volume 19, Issue 5, Page 1347-1370, May 2025.CD226+CD8+ T cells express elevated levels of RUNX2, exhibit higher proliferation capacity, cytokines and cytolytic molecules expression, and migratory capacity. In contrast, CD226−CD8+ T cells display an exhausted phenotype associated with the increased expression of co‐inhibitory receptors and impaired effector functions.
Maryam Rezaeifar +4 more
wiley +1 more source
Molecular Oncology, Volume 19, Issue 5, Page 1452-1470, May 2025.Pancreatic ductal adenocarcinoma (PDAC) is a disease with very poor prognosis due to therapeutic limitations. We investigated the antitumor effects of cystatin A (CSTA) in PDAC murine models. We are first to confirm that CSTA enhances T helper type 1‐mediated antitumor effects through promotion of dendritic cells and M1 macrophage activity. CSTA can be
Alessandro Nasti +8 more
wiley +1 more source
Cell‐free DNA aneuploidy score as a dynamic early response marker in prostate cancer
Molecular Oncology, EarlyView.mFast‐SeqS‐based genome‐wide aneuploidy scores are concordant with aneuploidy scores obtained by whole genome sequencing from tumor tissue and can predict response to ARSI treatment at baseline and, at an early time point, to ARSI and taxanes. This assay can be easily performed at low cost and requires little input of cfDNA. Cell‐free circulating tumor
Khrystany T. Isebia +17 more
wiley +1 more source
Molecular Oncology, Volume 19, Issue 4, Page 1092-1116, April 2025.FOXL2 c.402C>G mutation drives granulosa cell tumors. Using CRISPR technology, we selectively corrected this mutation, reducing malignancy and increasing sensitivity to dasatinib and ketoconazole. Transcriptomic changes revealed potential therapeutic targets, demonstrating CRISPR's promise for treating this rare ovarian cancer.
Sandra Amarilla‐Quintana +17 more
wiley +1 more source
Molecular Oncology, Volume 19, Issue 4, Page 984-993, April 2025.Tumor‐informed whole‐genome sequencing (MRD‐EDGESNV) was applied to detect circulating tumor DNA (ctDNA) in patients with colorectal adenomas. Using a 95% specificity threshold, established from stage III colorectal cancer patients, ctDNA was detected in 50% of symptomatic and 25% of asymptomatic adenoma cases with median tumor fractions of 5.9 × 10−5 ...
Amanda Frydendahl +13 more
wiley +1 more source
Rare decays of the Z and the standard model, 4th generation, and beyond
, 1989 T J Weiler
openalex +1 more source
Molecular Oncology, EarlyView.Prostate cancer is a leading malignancy with significant clinical heterogeneity in men. An 11‐gene signature derived from dysregulated epithelial cell markers effectively predicted biochemical recurrence‐free survival in patients who underwent radical surgery or radiotherapy.
Zhuofan Mou, Lorna W. Harries
wiley +1 more source
Clinical significance of stratifying prostate cancer patients through specific circulating genes
Molecular Oncology, Volume 19, Issue 5, Page 1310-1331, May 2025.We tested a specific panel of genes representative of luminal, neuroendocrine and stem‐like cells in the blood of prostate cancer patients, showing predictive value from diagnosis to late stages of disease. This approach allows monitoring of treatment responses and outcomes at specific time points in trajectories.
Seta Derderian +12 more
wiley +1 more source